MEMPHASYS LIMITED. — Capital/Financing Update 2011

Jul 26, 2011

==> picture [196 x 25] intentionally omitted <==

==> picture [196 x 25] intentionally omitted <==

==> picture [196 x 25] intentionally omitted <==

==> picture [196 x 24] intentionally omitted <==

FOR IMMEDIATE RELEASE

==> picture [49 x 49] intentionally omitted <==

NuSep Signs Letter of Intent with United Laboratories to Invest in Singapore & Philippines Plasma Facilities

Sydney, Australia 27[th] July 2011 - NuSep (ASX: NSP) is pleased to advise the market that it has signed a Letter of Intent with United Laboratories Inc of the Philippines ( Unilab ) for a potential investment in NuSep’s Singapore plasma fractionation facility and a concurrent new plasma fractionation facility to be established in the Philippines. These investments are dependent on due diligence to be conducted by Unilab and on terms to be negotiated by both parties which will begin in August 2011.

Unilab (www.unilab.com.ph) is a Philippines based pharmaceutical company that develops, manufactures and markets a wide range of prescription and consumer health products covering all major therapeutic categories. Unilab sells into the Philippines, Indonesia, Thailand, Malaysia, Singapore, Hong Kong, Vietnam and Myanmar markets and operates a biotech business in China.

Unilab understands the potentially game changing nature of the PrIME process and wishes to explore a direct investment into in the Singapore plasma facility and concurrently establish a plasma fractionations facility in the Philippines. Unilab see the Philippine facility as a stepping stone into the other markets it serves. Whilst the details of the Philippines plasma fractionation facility are still to be negotiated NuSep expects that its contribution to this project will be limited to providing the technology and assistance in setting up the Philippines plant.

Mr John Manusu, NuSep’s Executive Chairman said, “This is a significant step forward as we now have the support of a Government and the interest of the pharmaceutical industry confirming the Singapore plasma fractionation project business model.”

Dr Hari Nair, Managing Director of NuSep added that “The involvement of United Laboratories provides commercial validation of the mini-mill plasma fractionation business plan. Both the recently announced EDB Singapore funding and this initiative drive home the true importance and commercial value of the PrIME technology i.e. the national imperative of all countries to be self-sufficient in the supply of their plasma products.”

MR Jose Maria Ochave, Senior Vice President for Business Development from Unilab said, “We are keen to work with NuSep to establish this new and critical project and assist the Philippines to become self-sufficient in its requirements for life saving therapeutic products.”

ENDS

NuSep Holdings Ltd 324 Burns Bay Rd Lane Cove NSW 2066

Contact Details Telephone +61 2 8415 7300 Facsimile +61 2 8415 7399

Email info@nusep.com Web www.nusep.com ABN 33 120 047 556

Postal Address P.O. Box 823 Lane Cove NSW 1595

– 2 –

For more information please contact:

Contact: Prakash Patel Company Secretary +61 2 8415 7300 prakash.patel@nusep.com

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteoIQ software enabling NuSep to offer a total Proteomics solution from Fraction to Function . The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world’s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep’s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

==> picture [12 x 17] intentionally omitted <==

• Gels – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.

==> picture [12 x 17] intentionally omitted <==

• Separation Instruments – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2009 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF and is expected to undergoing clinical trials later this year.

==> picture [12 x 17] intentionally omitted <==

• Proteomics Software – NuSep offers the unique ProteoIQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.

==> picture [12 x 17] intentionally omitted <==

• Biological Products – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company’s website www.NuSep.com

About SingaPharm

SingaPharm is a Singapore based biotech company that has developed a disposable procedure for the processing of plasma proteins. SingaPharm is currently a wholly owned subsidiary of NuSep Holdings Limited (ASX: NSP). SingaPharm’s process is based on the Pr eparative I solation by M embrane E lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is ‘electronically’ driven membrane fractionation.

This process is flexible and modular compared with the large scale inflexible processing facilities of existing fractionators in US and Europe. The process has increased product yield relative to the existing process with increased product safety. The flexible nature of the PrIME technology also provides SingaPharm with access to plasma volumes that previously did not meet the criteria for larger scale processing facilities. Further, SingaPharm’s process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.